15 assets in Lung Large Cell Carcinoma

Therapeutic assets addressing Lung Large Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P4	A (80)
Cis-Diamminedichloroplatinum Ii Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P3	BBB (74)
Etoposide Lung Large Cell Carcinoma	Barbara Ann Karmanos Cancer Institute	P3	BBB (73)
Vinorelbine Ditartrate Lung Large Cell Carcinoma	AIO-Studien-gGmbH	P3	BB (70)
Docetaxel Lung Large Cell Carcinoma	Korean South West Oncology Group	P3	BB (69)
Cyclophosphamide Lung Large Cell Carcinoma	Intima Bioscience, Inc.	P2	B (63)
Methoxyamine Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Durvalumab Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Nivolumab Lung Large Cell Carcinoma	M.D. Anderson Cancer Center	P2	B (57)
Pegfilgrastim Lung Large Cell Carcinoma	Wake Forest University Health Sciences	P2	B (57)
Nivestim Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Veliparib Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Cish Inactivated Tumor Infiltrating Lymphocytes Lung Large Cell Carcinoma	Intima Bioscience, Inc.	P1/2	CCC (48)
Fludarabine Lung Large Cell Carcinoma	Intima Bioscience, Inc.	P1/2	CCC (48)
Pembrolizumab Lung Large Cell Carcinoma	Intima Bioscience, Inc.	P1/2	CCC (48)